Shares of Hims & Hers Health experienced a notable increase following the announcement by Health and Human Services Secretary Robert F. Kennedy Jr. that the FDA plans to convene a Pharmacy Compounding Advisory Committee meeting to discuss the potential inclusion of peptides on the 503A bulk list. This designation allows for drugs to be compounded based on individual prescriptions rather than mass production.
Hims & Hers has been developing its peptide business for several years, positioning itself to tap into this evolving market. Peptides—short chains of amino acids—are being explored for various health applications but face skepticism due to limited scientific evidence regarding their long-term safety and effectiveness. The company’s momentum in this area intensified with its acquisition of a peptide facility in California in early 2025, which CEO Andrew Dudum described as a step towards “future-facing innovation.”
Dr. Patrick Carroll, Chief Medical Officer at Hims, praised the FDA’s forthcoming review as a move toward regulated therapeutic options, aiming to distance peptide therapy from the “gray market.” He emphasized the potential benefits certain peptides could offer in improving public health.
Investment firm Leerink Partners view the FDA’s review positively, suggesting it could pave the way for Hims to develop scaled peptide therapies, though they caution that immediate revenue growth is unlikely. The stock, trading around $26, reflects investor optimism, with analysts noting the company may push aggressively into the peptide sector.
However, the discussion around peptides remains controversial. Some substances on the potential compounding list have been classified as illegal or banned in sports, while others lack strong scientific validation. Despite these challenges, the exploration of peptides presents Hims with a promising opportunity as it seeks new growth avenues post-GLP-1.
Why this story matters
Key takeaway
Opposing viewpoint
